Source

Human B7-H6 (H-B7H6-1) is expressed from human 293 cells (HEK293). It contains AA Asp 25 - Ser 262 (Accession # Q68D85-1).

Predicted N-terminus: Asp 25

Molecular Characterization

This protein carries a polyhistidine tag at the C-terminus.

Endotoxin

Less than 0.01 EU/mg by the LAL method.

Purity

>95% as determined by SDS-PAGE.

Bioactivity

ELISA ；

BIACORE (With our Research Grade Biosimilar Antibody products);

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

No activity loss was observed after storage at:

4-8°C for 12 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

Background

The B7 family of genes is essential in the regulation of the adaptive immune system. one of which is the recently discovered B7H6. Humans and rats have a single B7H6 gene; however, many B7H6 genes were detected in a single large cluster in the Xenopus genome. \rChimeric antigen receptor (CAR) T-cell therapies have demonstrated durable and potentially curative therapeutic efficacy against B-cell leukemia in clinical trials. In this study, B7H6, a ligand for the NK cell activating receptor NKp30, was targeted to create a CAR that targets multiple tumor types. B7H6 is expressed on various primary human tumors, including leukemia, lymphoma and gastrointestinal stromal tumors, but it is not constitutively expressed on normal tissues.

Reference

(1) Wu MR, et all., 2015, Gene Ther.22(8):675-84.

(2) Phillips M, et all., 2016, Biopolymers. 106(5):658-72.

(3) Flajnik MF, et all., 2012 Immunogenetics. 64(8):571-90.